USPCM
EGRX

Union Square Park Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Union Square Park Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-56,963
Closed -$212K – 45
2024
Q3 		$212K Buy
+56,963
New +$272K 0.15% 34

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $508M AUM 24.79% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Union Square Park Capital Management's EGRX Position: Q4 2024 in Review

Union Square Park Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 56,963 shares — an estimated $212K sold.

Union Square Park Capital Management first reported a position in EGRX in Q3 2024 and held it in 1 quarter. The position peaked at $212K in Q3 2024. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • Union Square Park Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • Union Square Park Capital Management sold 56,963 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $212K.
  • Union Square Park Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2024 and held it in 1 quarter.
  • Union Square Park Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $212K in Q3 2024.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Union Square Park Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.